Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
454.58
-5.00 (-1.09%)
Oct 8, 2025, 10:31 AM EDT - Market open
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,104,019
Profits / Employee
-$143,089
Market Cap
59.59B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,230 | 130 | 6.19% |
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALNY News
- 7 days ago - Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
- 9 days ago - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
- 14 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript - Seeking Alpha
- 20 days ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire
- 27 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes - Business Wire
- 4 weeks ago - Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes - Business Wire
- 4 weeks ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript - Seeking Alpha